Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0635-y
Abstract: The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders… read more here.
Keywords: dm1; trastuzumab emtansine; resistance; emtansine dm1 ... See more keywords
Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033677
Abstract: Human epidermal growth factor receptor 2 (HER2)-targeting therapies have become crucial in the management of HER2-positive breast cancer. Trastuzumab emtansine (T-DM1) is a microtubule inhibitor and HER2-targeted antibody conjugate. T-DM1 resistance is most likely influenced… read more here.
Keywords: trastuzumab emtansine; her2; emtansine dm1; breast cancer ... See more keywords
Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21654
Abstract: D EAR E DITOR , A 46-year-old woman with invasive lobular carci-noma of the breast presented to the oncodermatology clinic for a growth on the ventral tongue that developed approxi-mately 6 months after initiation of… read more here.
Keywords: trastuzumab emtansine; emtansine dm1; mucosal haemangioma; treatment ... See more keywords
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.100
Abstract: 100Background: The NCI-MATCH is the largest national signal-finding trial incorporating centralized genomic testing to direct pts to molecularly targeted phase 2 treatment arms. HER2 gene amp is ob... read more here.
Keywords: dm1 patients; trial; match; trastuzumab emtansine ... See more keywords